Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Savara Announces Appointment of Peter Ginsberg as Vice President of Business Development

2018-01-04 marketwired
AUSTIN, TX--(Marketwired - January 04, 2018) - Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that Peter Ginsberg has joined the company as Vice President of Business Development. An accomplished orphan lung disease business development and investment executive, Mr. Ginsberg brings to Savara a wealth of experience in biopharma business development and strategic planning, in addition to a unique perspective as a former senior biotechnology analyst and healthcare institutional investor. (22-0)

BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates

2017-11-10 zacks
BioDelivery Sciences International, Inc. (BDSI - Free Report) reported a loss of 21 cents per share in the third quarter of 2017, narrower than both the Zacks Consensus Estimate of a loss of 22 cents and the year-ago loss of 30 cents. (30-3)

BioDelivery Sciences International, Inc. 2017 Q3 - Results - Earnings Call Slides

2017-11-09 seekingalpha
The following slide deck was published by BioDelivery Sciences International, Inc. in conjunction with their 2017 Q3 earnings call. (5-2)

BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?

2017-11-07 zacks
BioDelivery Sciences International, Inc. (BDSI - Free Report) is scheduled to report third-quarter 2017 results on Nov 9 after market close. Last quarter, the company delivered a negative earnings surprise of 8%. (87-0)

BRIEF-BioDelivery sciences announces patent litigation settlement agreement with Teva

2017-10-12 reuters
* BioDelivery Sciences - ‍as part of settlement agreement, co has entered into a non-exclusive license agreement with Teva ​ (5-0)

BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva

2017-10-12 prnewswire
RALEIGH, N.C., Oct. 12, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc., Actavis Laboratories UT, Inc. and Teva Pharmaceuticals Industries, Ltd. (Teva) that resolves BDSI's previously reported BUNAVAIL® patent litigation against Teva pending in the United States District Court for the District of Delaware. (22-0)

BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence

2017-10-06 prnewswire
RALEIGH, N.C., Oct. 6, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) participated in a round table meeting convened this week in Washington, D.C. by the U.S. Department of Health and Human Services (HHS) to discuss efforts to advance pain management therapies and the treatment of opioid dependence as well as advancing alternative therapies. BDSI was represented by its Vice Chairman, President and Chief Executive Officer, Dr. (22-0)

BioDelivery Sciences (BDSI) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow

2017-09-27 seekingalpha
The following slide deck was published by BioDelivery Sciences International, Inc. in conjunction with this event. (5-0)

BioDelivery Sciences (BDSI) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow

2017-09-26 seekingalpha
The following slide deck was published by BioDelivery Sciences International, Inc. in conjunction with this event. (5-0)

BioDelivery Sciences to Present Three Posters on BELBUCA® and BUNAVAIL® at PAINWeek 2017

2017-08-17 prnewswire
RALEIGH, N.C., Aug. 17, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will present three posters reviewing the potential impacts of BELBUCA® (buprenorphine) buccal film (CIII) and BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) on important issues pertinent to the opioid epidemic, such as safety and diversion, at the PAINWeek 2017 meeting in Las Vegas, NV on September 5 - 9, 2017.

BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls

2017-08-10 zacks
BioDelivery Sciences International, Inc. (BDSI - Free Report) reported a loss of 27 cents per share in the second quarter of 2017, which was wider than the Zacks Consensus Estimate of a loss of 25 cents. The company had reported a loss of 31 cents per share in the year-ago quarter.

BioDelivery Sciences International's (BDSI) CEO Mark Sirgo on Q2 2017 Results - Earnings Call Transcript

2017-08-10 seekingalpha
Good day and welcome to the BioDelivery Sciences Second Quarter 2017 Earnings Call. Today's conference is being recorded.

What's in Store for BioDelivery (BDSI) This Earnings Season?

2017-08-08 zacks
BioDelivery Sciences International, Inc. (BDSI - Free Report) is scheduled to report second-quarter 2017 results on Aug 9 after market close. Last quarter, the company’s earnings surpassed expectations.

CUSIP: 09060J106